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Abstract
Background/Aims: Liver biopsy represents the gold standard for damage evaluation, but noninvasive serum markers that
mirror liver fibrosis progression are actual goals both in adults and especially in children. The aim was to determine specific
serum markers that correlate with liver fibrosis progression during chronic HCV infection.
Methods: Liver biopsies and concomitant serum samples from 22 pediatric and 22 adult HCV patients were analyzed.
Histological parameters were evaluated. On serum TGF-ß1, tissue inhibitor of matrix metalloprotein inhibitor-1 (TIMP-1),
hyaluronic acid (HA) and aminoterminal peptide of procollagen type III (PIIINP) were tested.
Results: Significant fibrosis (F$2) and advanced fibrosis (F$3) represented 64% and 20%, respectively in children; while 54%
F$2 and 23% F$3 in adults. Hyaluronic acid (p=0.011) and PIIINP (p=0.016) were related to worse fibrosis stages only in
adults, along with TIMP-1 (p=0.039) just in children; but TGF-ß1 was associated with mild fibrosis (p=0.022) in adults. The
AUROC of TIMP-1 in children to discriminate advanced fibrosis was 0.800 (95%IC 0.598–0.932). In adults, the best AUROCs
were that of HA, PIIINP and TGF-ß1 [0.929 (IC95% 0.736–0.994), 0.894 (IC95% 0.689–0.984) and 0.835 (IC95% 0.617–0.957)],
respectively. In children, according to the cut off (165.7 ng/mL) value for TIMP-1, biopsies could have been avoided in 72%
(18/25). Considering the cut off for HA (109.7 ng/mL), PIIINP (9.1 mg/L), and TGF-ß1 (10,848.3 pg/mL), biopsies could have
been avoided in 87% (19/22) of adult patients by using HA and 73% (16/22) using PIIINP or TGF-ß1.
Conclusions: In adults given the diagnostic accuracy of HA, PIIINP, TGF-ß1, their combination may provide a potential useful
tool to assess liver fibrosis. This first pediatric study suggests that TIMP-1 is clinically useful for predicting liver fibrosis in HCV
patients.
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Introduction
Hepatitis related to HCV is a progressive disease that may
result in chronic active hepatitis, cirrhosis, and hepatocellular
carcinoma [1,2,3]. It represents a global health problem since
there is no vaccine currently available and furthermore, liver
failure due to chronic hepatitis C (CHC) is one of the most
common reasons for liver transplants. Liver disease seems to be
milder in children than in adults; however, the natural history of
chronic HCV infection acquired in infancy and childhood
remains poorly characterized and the long-term outcome of the
disease is still a matter of debate [4,5]. The mechanisms leading
to liver cell injury, inflammation, steatosis and fibrosis are still
under study. Staging liver fibrosis is considered to be an essential
part in the management of patients with CHC, because it
provides prognostic information and, in many cases, assists in
therapeutic decisions [6]. Although liver biopsy represents the
gold standard for evaluating presence, type and stage of liver
fibrosis and for characterizing necroinflammation; it remains a
costly and invasive procedure with inherent risks. Thus, it
cannot be performed frequently to monitor therapeutic out-
comes [7,8]. Moreover, in children, biopsy is still perceived to
carry a higher risk of complications, so it is less accepted than in
adults. Therefore, developing noninvasive tests that can
accurately predict initial disease stage and progression over time
represents a high priority and growing medical need [9,10].
Currently, there are several noninvasive diagnostic methods for
determining liver fibrosis that are being validated such as blood
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clinical practice [11].
In recent years, many studies have been dedicated to the
evaluation of noninvasive indirect serum markers of fibrosis such
as serum aminotransferases, aspartate aminotranferase (AST)-to-
platelet ratio (APRI) and AST-to-alanine aminotranferase (ALT)
ratio (AAR), but they reflect alterations in hepatic function rather
than in extracellular matrix metabolism. Since, several HCV
reports have described normal aminotransferase levels in about
25%–30% CHC patients, there may be a potential advantage in
assessing serum direct fibrosis markers that do not involve
transaminases [4,12,13,14]. The extracellular matrix remodelling
markers represent attractive candidates because they measure
directly the fibrogenic process that leads to clinical complications
[15]. These markers include several glycoproteins (hyaluronan,
laminin etc), the collagen family (procollagen III, type IV collagen
and type IV collagen 7s domain), collagenases and their inhibitors
(metalloproteinases and tissue inhibitors of metalloproteinases) and
a number of cytokines involved in the fibrogenic process (in
particular TGF-ß1). These have been analysed individually as well
as combined, in order to assess severity and progression of hepatic
fibrosis and to follow up changes related to viral treatment
[16,17,18,19,20,21,22,23].
On the other hand, many authors have combined several
biochemical and clinical data (i.e. Fib-4, Forns, Fibrotest) to
predict fibrosis stages, but others have brought these together with
serum fibrosis markers (i.e. Hepascore, SHASTA, Fibrometer) to
do so. [24,25,26]. However, this calculation system is tough and
complicated to perform routinely in every case.
Finally, considering that most noninvasive approaches for
evaluating liver fibrosis have been performed in adults and taking
into account the above mentioned considerations about biopsies,
there is a clear need to assess these markers in children. Hence, the
purpose of our study was to evaluate the presence of a pro-
fibrogenic cytokine (TGF-ß1) and matrix deposition markers
[hyaluronic acid (HA), type III procollagen amino-terminal
peptide (PIIINP) and tissue inhibitor of matrix metalloprotein
inhibitor-1 (TIMP-1)] that correlate with liver injury during
chronic hepatitis C virus infection, in a cohort of pediatric and
adult patients.
Methods
Patients and samples
Twenty two pediatric patients with chronic HCV infection (8
male, 14 female; range of age at biopsy: 1–17 years, median: 8
years) who attended the Ricardo Gutierrez Children’s Hospital;
and 22 adult patients (13 male, 9 female; range of age at biopsy:
38–74 years, median: 51 years) from Hospital Italiano de Buenos
Aires were enrolled in the present study.
Diagnosis was based on the presence of anti-HCV antibodies in
serum at or after 18 months of age and HCV RNA in plasma at
one or more separate occasions. Patients had no other causes of
liver disease, autoimmune or metabolic disorders, hepatocellular
carcinoma and coinfection with hepatitis B virus and/or human
immunodeficiency virus. In adult cases, patients with a history of
habitual alcohol consumption were excluded (.80 g/day for men
and .60 g/day for women). Patients were naı ¨ve of treatment.
This study has the approval of the Institutional Review Board and
the Ethics Board of both Ricardo Gutierrez Children Hospital and
Hospital Italiano de Buenos Aires and is also in accordance with
the Helsinki Declaration of 1975, as revised in 1983. A written
informed consent was obtained from all the included adult patients
and from parents of pediatric patients after the nature of the
procedure had been fully explained.
Formalin-fixed paraffin-embedded liver biopsies and serum
samples at time of biopsy were used for histological and serological
analysis, respectively. Histological sections were evaluated by two
independent pathologists in a blind manner. Fibrosis staging were
semiquantitatively assessed according to the METAVIR system
[27]. Serum samples were stored frozen at 280uC. Serum AST
and ALT levels, HCV viral load and genotype, smoking status and
alcohol consumption were obtained from clinical records. In
pediatric patients, normal ALT and AST levels were #32 and
#48 IU/L, respectively. In adult patients, normal ALT and AST
levels were #40 and #42 IU/L, respectively. In two pediatric
cases, more than one sample was analyzed. As controls, serum
samples from pediatric (n=9) and adult (n=9) healthy subjects
without known systemic or liver disease and with normal biological
liver test as well as absence of anti-HCV antibodies, were included.
In adult cases, liver samples were not obtained from patients
diagnosed as having liver cirrhosis based on clinical, biochemical
and imaging findings. Although, there are no pediatric specific
guidelines about the need for and timing of a liver biopsy in
children, the probability of a child undergoing liver biopsy in this
study reflected the current practice at our centre, which is based
mostly on the national experts consensus [28].
Quantitative measurement of human TGF-ß1, TIMP-1, HA
and PIIINP
Serum TGF-ß1 and TIMP-1 were determined by commercial
quantitative sandwich enzyme immunoassay technique (Quanti-
kine, R&D System Inc) according to the manufacturer’s
instructions. Serum concentration for each marker was deter-
mined from the constructed standard curves. Serum TGF-ß1 was
expressed as pg/mL and TIMP-1 as ng/mL.
Serum HA levels were assessed by ELISA (Corgenix) according
to the manufacturer’s instructions. The HA test kit is an enzyme-
linked binding protein assay that uses a capture molecule known as
hyaluronic acid binding protein (HABP) and an enzyme-
conjugated version of HABP. Hyaluronic acid levels in patient
and control samples were determined from the constructed
reference curve and expressed as ng/mL.
The levels of PIIINP were measured using a commercial
competitive radioimmunoassay technique (UNniQ, Orion Diag-
nostica) according to manufacture’s instructions. Concentrations
of PIIINP (mg/L) were obtained from a calibration curve.
Each serum marker concentration was assessed in duplicate.
Operators who perform the laboratory tests were blinded for
patient’s clinical and histological data.
Statistical analysis
Statistical analysis was performed using GraphPad InStat
software, version 3.05. To compare the means between groups,
ANOVA or Student’s t test were performed. To determine
differences between groups not normally distributed, medians
were compared using the Mann-Whitney U test or Kruskal Wallis
test. Pearson’s correlation coefficient was used to measure the
degree of association between continuous, normally distributed
variables. The degree of association between non-normally
distributed variables was assessed using Spearman’s nonparamet-
ric correlation. To compare categorical variables Fisher’s exact
Test was applied. P values,0.05 were considered statistically
significant. Results of serum fibrosis markers were expressed as
box plots.
To assess the ability of the four serum fibrosis markers for
differentiating significant (F$2) and advanced fibrosis (F$3), we
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fibrosis marker and then constructed receiver operating charac-
teristic (ROC) curves by plotting the sensitivity against the reverse
specificity at each value. The diagnostic value of each serum
marker was assessed by the area under the ROC (AUROC).
AUROC of 1.0 is characteristic of an ideal test, whereas 0.5
indicates a test of no diagnostic value. We determined the cut-off
value for the diagnosis, as the maximal value at the sum of the
sensitivity (Se) and specificity (Sp). The diagnostic accuracy was
calculated by sensitivity, specificity and positive and negative
predictive values, considering significant and advanced fibrosis of
the disease. Area under the ROC, cut off values, positive
predictive values (PPV) and negative predictive values (NPV) were
determined using the MedCalc demo statistical software (Mar-
iakerke, Belgium).
Due to the heterogeneous distribution of fibrosis stages on liver
biopsies, we applied the DANA method described by Poynard et al
[29]. The DANA is an index for standardizing comparisons in
order to transform any different fibrosis prevalence profile into a
homogeneous distribution of fibrosis stages from F0 to F4, as
defined by a prevalence of 0.20 for each of the five METAVIR
stages (standard prevalence). The DANA method was applied for
each biological non-invasive test. The formula to calculate the
adjusted AUROC (AdAUROC) according to a uniform DANA of
2.5 was ObservedAUROC+(0.1056) (2.5-ObservedDANA). Ob-
served AUROC represents the AUROC of the studied group [29].
Finally, we calculated the percentage of patients in whom the
results of each serum marker could have avoided the biopsy.
Patients correctly classified [true positive (TP)+true negatives
(TN)] by a certain test would not have needed the biopsy
procedure.
Results
1. Clinical and liver biopsy findings
Clinical, virological, and histological features of patients are
described in Table 1 (pediatric patients) and Table 2 (adult
patients).
In both groups genotype 1 was predominant. It was present in
86% of pediatric cases and 77% of adult cases. Only one pediatric
patient displayed genotype 4, two adults genotype 2 and three
adults genotype 3. The risk factors for HCV infection in pediatric
cases were maternal HCV infection in 46% of patients (10/22),
transfusion in 36% (8/22) and unknown in 18% (4/22). In adults,
seven cases (32%) had a history of injecting drug abuse, one case
(5%) described an occupational exposure to infected blood, four
(18%) a transfusion as a risk factor and 10 (45%) an unknown
source for transmission. The AST and ALT levels at time of biopsy
(considering multiple biopsies from the same patient in 2 pediatric
cases) were elevated in 52% (13/25) and 76% (19/25) serum
samples of pediatric patients, respectively and in 59% (13/22) and
77% (17/22) serum samples of adult patients as well.
Concerning fibrosis, bridging fibrosis was predominant among
studied pediatric biopsies (44%). However, one case harbouring
thalassemia displayed complete cirrhosis and one case, with an
actual progression of liver disease during follow up, incomplete
cirrhosis. In adult cases, the fibrosis profile displayed 32% stage 1,
32% stage 2 and 23% stage 3. Finally, three adult patients showed
absence of fibrosis. The prevalence of significant fibrosis (F$2) and
advanced fibrosis (F$3) in the pediatric cohort were 64% and
20%, respectively; meanwhile it was 54% F$2 and 23% F$3i n
adults.
The comparative statistical analysis of all histological parame-
ters between adult and pediatric patients studied did not show any
significant difference. However, it should be taken into account
that adult cases with liver cirrhosis based on clinical, biochemical
and imaging findings were not biopsied.
Aminotransferase values showed no statistical correlation with
fibrosis stages (AST r=0.04, p=0.85 and ALT r=0.08, p=0.70
in pediatrics; AST r=0.14, p=0.50 and ALT r=0.05, p=0.81 in
adults), as well as viral load did not correlate with it either
(r=0.55, p=0.12 in pediatric patient, r=0.26, p=0.31 in adults).
Concerning gender, it has no statistically significant difference
related neither to advanced nor significant fibrosis in any of the
studied series (p=1.0 for F$3, p=0.23 for F$2 in pediatric
patients; p=0.11 for F$3, p=0.41 23 for F$2 in adults. With
regards to the smoking status, none of the pediatric patients is a
smoker and in the adult cohort, 12 were no smokers, 7 were
smokers and there were no available data in the medical records
for the other 3. Smoking status showed no statistically significant
difference related either to advanced or significant fibrosis in the
studied adult series [Adults F$2( p=1), Adults F$3( p=0.60)].
2. Quantitative measurement of TGF-ß1, TIMP-1, HA and
PIIINP
Serum concentrations of studied markers were compared
between HCV patients and control healthy subjects. In chronic
HCV patients TGF-ß1, TIMP-1, HA and PIIINP levels were
higher than in controls (Table 3).
Serum TGF-ß1 showed no statistically significant differences
among fibrosis stages in pediatric patients; however it was
associated with mild fibrosis (p=0.022) in adults (Figure 1). Higher
values of TIMP-1 and HA were observed in both pediatric and
adult patients with worse fibrosis stages. The same pattern was
observed with PIIINP in adults, but not in children (Figure 1).
However, the differences among fibrosis stages were significant for
HA (p=0.011) and PIIINP (p=0.016) only in adults, along with
TIMP-1 (p=0.039) just in children.
Interestingly, the uppermost values for HA (228.2 ng/mL) and
TIMP-1 (845.2 ng/mL) in children correspond to a patient with
complete cirrhosis. In adults, the extremely elevated HA value
(2,225 ng/mL; result confirmed in three independent assay) and
the TIMP-1 (977.5 ng/mL) and PIIINP (39.42 mg/L) uppermost
values correspond to the case with stage 4 fibrosis according to
modified Knodell scoring system.
3. Diagnostic performance of serum markers for
significant and advanced fibrosis
The efficiency of these markers to differentiate significant (F$2)
and advanced fibrosis (F$3) were evaluated using ROC (Figure 2).
Table 4 showed the best AUROC for the four serum fibrosis
markers. These AUROCs had low but similar diagnostic
accuracies for significant fibrosis. In the pediatrics cohort, the
best AUROC was that of TIMP-1, which discriminates advanced
fibrosis from other stages, with an AUROC of 0.800. On the other
hand, in adults, the best AUROCs were that of HA, PIIINP and
TGF-ß1 (0.929, 0.894 and 0.835, respectively). For most markers,
the accuracy for discriminating significant fibrosis was lower than
that for discriminating advanced fibrosis.
Standardization of AUROC by DANA method was carried out
for each marker. The analysis showed that AdAUROC were
always higher than the corresponding AUROC, but these
increments were not significant (Table 4)
Cut off values for each marker in both cohorts for significant
and advanced fibrosis stages were shown in Table 5. Many fibrosis
experts would consider noninvasive tests for fibrosis with an
AUROC value of 0.850–0.900 to be as good as liver biopsies for
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to be predictors of fibrosis. In this analysis, those markers with
AUROCs higher than 0.800 were only considered. The cut off
value for pediatric TIMP-1 in advanced fibrosis was 165.7 ng/mL
(80% sensibility, 70% specificity). In adults, the cut-off values of
HA, PIIINP and TGF-ß1 were 109.7 ng/mL, 9.1 mg/L and
10,848.3 pg/mL respectively. The sensitivity and specificity for
these cut off values were 100% and 82.3% for HA, 100% and
64.7% for PIIINP and 100% and 64.7% for TGF-ß1, respectively.
Although PIIINP for F$2 and HA for F$3 in pediatric patients
had an excellent 100% PPV (Table 5), the diagnostic values were
quite low (PIIINP AUROC: 0.648 and HA AUROC: 0.562)
(Table 4). The same was observed in adults’ TIMP-1 for F$3
(AUROC: 0.553) (Table 4). The NPV was quite low for all the
non-invasive markers of F$2 in children (always ,67%), so that
significant fibrosis could not be reliably excluded by any of these
markers. The noninvasive methods with best AUROCs (TIMP-1
in the pediatric cohort and HA, PIIINP and TGF-ß1 in adults)
showed high NPV (.90%) for advanced fibrosis.
In children, according to the cut off values for advanced fibrosis
(F$3), using TIMP-1 as a serum marker, 14 of 20 (70%) patients
with F,3 were correctly categorized, while only 1 of 5 (20%)
patients with F$3 were misclassified (40% PPV and 93.3% NPV).
Considering the above, biopsies could have been avoided in 72%
(18/25) of pediatric patients. In adults, when the cut-off value for
HA was applied, 19 patients were correctly classified (5 patients
were TP and 14 patients were TN), and 3 patients were
misclassified [False Positive (FP)]. Taking into consideration the
cut off for PIIINP, 16 patients were correctly identified (5 patients
were TP and 11 patients were TN), and 6 patients were
misclassified (6 FP). According to the cut off value for TGF-ß1,
16 patients were correctly identified (5 patients were TP and 11
patients were TN), and 6 patients were misclassified (6 FP).
Consequently, biopsies could have been avoided in 87% (19/22) of
adult patients by using HA and 73% (16/22) using PIIINP or
TGF-ß1.
Discussion
A major clinical challenge is finding the best means for
evaluating liver impairment and managing the increasing
number of HCV infected patients. Prognosis and treatment of
CHC are partly dependent on the assessment of histological
activity, namely cell necrosis and inflammation, and on the
Table 1. Clinical, virological and histological features of HCV pediatric patients.
Clinical and serological characteristics Histological characteristics
Pediatric
Patients Sex
Ages
(ys)
Risk factor for
HCV infection Genotype Transaminases Knodell
Lymphoid
Follicle
Bile duct
damage Steatosis
AST (U/L) ALT (U/L)
1 M 1 3 T 1 a 4 74 38 ( 5 +3) no no absent
2 F 1 4 T 1 b 5 58 61 1 ( 9 +2) no no minimal
3 F 4 V 1a/c 46 34 10(7+3) yes yes absent
4 F 17 T 1a/c 39 43 8(4+4) no yes moderate
5 M 4 V 1a/c 84 97 10(9+1) yes yes severe
6 BxI F 6 V 1a/c 13 11 7(3+4) no no absent
BxII 13 23 21 8(5+3) no yes minimal
7 F 16 Unknown 1a/c 30 41 12(10+2) yes yes minimal
8 BxI M 3 V 1a/c 71 91 6(5+1) yes yes minimal
BxII 6 314 364 11(8+3) no yes severe
BxIII 13 225 260 21(16+5) no yes moderate
9 F 6 V 1a/c 35 50 8(7+1) yes yes minimal
10 F 8 Unknown 1a 41 38 9(7+2) yes yes absent
11 M 13 Unknown ND 56 71 10(7+3) no yes absent
12 F 17 V 1a/c 21 11 6(3+3) no yes minimal
13 F 3 V 1a/c 84 137 6(5+1) no yes moderate
1 4 F 3V 1 b 6 57 59 ( 6 +3) yes yes moderate
15 F 1 V 4 57 33 11(7+4) yes yes absent
16 F 17 T 1a/c 22 16 10(7+3) no yes minimal
17 M 1 T 1b 159 213 14(11+3) yes yes minimal
1 8 F 8T 1 b 1 01 26 ( 5 +1) no no absent
19 M 15 T ND 58 76 16(10+6) no yes absent
20 F 6 V 1a/c 56 55 6(5+1) no yes severe
21 M 15 T 1b 20 24 13(10+3) yes yes absent
22 M 12 Unknown 1a/c 83 113 11 (8+3) no yes minimal
F: female, M: male. ND: not determined Bx I, Bx II, Bx III denote: multiple liver biopsies. Risk factor for HCV infection: T: transfusion, V: maternal HCV infection.
ALT: alanine aminotransferase; AST: aspartate aminotransferase. Normal ALT and AST levels were #32 and #48 IU/L, respectively when test was done at 37uC.
doi:10.1371/journal.pone.0023218.t001
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provided by liver biopsy, because conventional laboratory tests
are unable to precisely evaluate liver lesions. Biopsy, because of
its limitations and risks, is no longer considered mandatory as
the 1st-line indicator of liver injury in HCV patients
[30,31,32,33]. In addition to the risks related to an invasive
procedure, liver biopsy has been associated with sampling error
mostly due to suboptimal biopsy size [34,35,36]. To avoid these
pitfalls, several markers have been proposed as noninvasive
alternatives for predicting fibrosis; but few, particularly those
which combine clinical and biochemical parameters, have been
applied to pediatric patients [37,38].
Table 2. Clinical, virological and histological features of HCV adult patients.
Clinical and serological characteristics Histological characteristics*
Adult
Patients Sex
Ages
(ys)
Risk factor for HCV
infection Genotype Transaminases Knodell
Lymphoid
Follicle
Bile duct
damage Steatosis
AST (U/L) ALT (U/L)
1 M 38 Unknown 1b 82 89 6(5+1) yes yes absent
2F 5 2 T 1 b4 5 5 2 8 ( 6 +2) yes yes minimal
3 M 42 Unknown 1a 44 56 9(8+1) yes yes absent
4 F 62 T 1a 42 32 11(7+4) no yes moderate
5 M 48 DA 1b 40 63 10(7+3) no yes severe
6 M 40 DA 1a 34 45 10(6+4) yes yes moderate
7 M 47 Unknown 1a 29 54 8(6+2) yes yes minimal
8 M 40 DA 2a 63 79 4(4+0) yes no absent
9 M 41 DA 3a 79 86 7(4+3) no yes absent
10 F 61 Unknown 1a 31 28 17(12+5) yes yes absent
11 F 72 Unknown 1a/c 52 71 9(6+3) yes yes minimal
12 F 74 T 1* 106 85 15(12+3) yes yes absent
13 M 62 Unknown 1b 22 32 10(7+3) no yes absent
14 F 55 Unknown 3b 49 60 8(6+2) yes yes severe
15 F 67 Unknown 2a 28 26 6(6+0) yes yes minimal
16 F 41 Unknown 1a 192 105 6(2+4) yes yes absent
17 M 51 OE 1b 65 74 5(4+0) yes yes absent
18 M 51 DA 1a 73 109 10(7+3) yes yes minimal
19 F 67 T 1b 106 103 13(9+4) yes yes absent
20 M 73 Unknown 1b 31 42 8(6+2) yes yes absent
21 M 41 DA 1a 32 50 10(7+3) yes yes severe
22 M 47 DA 3 38 59 3(2+1) yes yes minimal
F: female, M: male.
*Subtype not determined Risk factor for HCV infection: T: transfusion, DA: drug abuse, OE: occupational exposure.
ALT: alanine aminotransferase; AST: aspartate aminotransferase. Normal ALT and AST levels were #40 and #42 IU/L, respectively when test was done at 37uC.
doi:10.1371/journal.pone.0023218.t002
Table 3. TGF-ß1, TIMP-1, HA and PIIINP levels in chronic HCV patients vs healthy subjects.
Pediatrics Adults
Healthy
* HCV+
* P value Healthy
* HCV+
* P value
TGF-ß1 (pg/ml) 2,866 12,178 ,0.0001 5,257 12,384 ,0.0001
(770.3–7,125) (1,400–24,407) (1,566–7,898) (2,151–25,679)
TIMP-1 (ng/ml) 79.75 142.9 0.0029 114.9 302.6 ,0.0001
(53.98–120.2) (71.66–845.2) (92.58–181.1) (113.5–977.5)
HA (ng/ml) 6.36 10.22 0.03 10.22 80.12 ,0.0001
(0–11.03) (2.67–228.2) (4.51–48.41) (7.90–2,225)
PIIINP (mg/L) 11.43 12.37 0.04 5.54 9.58 0.0004
(8.64–13.65) (6.91–27.77) (3.30–6.61) (3.41–39.42)
*Results are expressed as median (min-max).
doi:10.1371/journal.pone.0023218.t003
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23218Figure 1. Serum markers related to fibrosis stages in chronic hepatitis C patients. A) TGF-ß1, B) TIMP-1, C) HA, D) PIIINP. Horizontal lines
inside each box represent the median, and the lower and upper borders of the box encompass the interquartile range. The vertical lines from the
ends of each box encompass the extreme data points. Fibrosis stages according to METAVIR. NS: no significant. * Note: different scale compared with
pediatric values.
doi:10.1371/journal.pone.0023218.g001
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balance between extracellular matrix (ECM) deposition and
removal [39]. It is characterized by the activation and proliferation
of hepatic stellate cells (HSCs) which undergo a phenotypic switch
when exposed to soluble factors including transforming growth
factor beta-1 (TGF-ß1) [40,41,42]. Hepatic stellate cells secret
excess matrix proteins such as collagens, elastin, glycoproteins, and
proteoglycans, then matrix degradation, initiated by a family of
enzymes called the matrix metalloproteins (MMPs), occurs. MMP
are in turn inhibited by tissue inhibitors of metalloproteins
(TIMPs) [17,43,44].
Hepatitis C virus Core protein is thought to be involved in the
disruption of lipid metabolism leading to the production of the
pro-inflammatory cytokine TGF-ß1 [45,46,47]. Hyaluronic acid
(HA) is synthesized and distributed throughout the extracellular
space by HSC, therefore its serum levels reflect the activity state of
these cells [48]. Tissue inhibitor of matrix metalloprotein
inhibitor-1 (TIMP-1) protects collagen from MMP fibrolysis and
also inhibits the apoptosis of HSC [49]. On the other hand,
initiating events in HSC activation are occurring on a background
of progressive disease changes in the surrounding ECM. Over the
time, the subendothelial matrix composition changes from one
Figure 2. AUROC of TGF-ß1, TIMP-1, HA and PIIINP in pediatric and adult cohorts A) for significant and B) for advanced fibrosis.
doi:10.1371/journal.pone.0023218.g002
Table 4. AUROC for significant and advance fibrosis.
Significant fibrosis (F$2)
Advanced fibrosis
(F$3)
AUROC 95% CI AdAUROC AUROC 95% CI
PEDIATRICS
TGF-ß1 0.549 0.339–0.746 0.661 0.570 0.359–0.764
TIMP-1 0.625 0.411–0.809 0.737 0.800 0.593–0.932
HA 0.585 0.368–0.780 0.697 0.562 0.347–0.762
PIIINP 0.648 0.417–0.836 0.760 0.694 0.464–0.870
ADULTS
TGF-ß1 0.792 0.567–0.933 0.875 0.835 0.617–0.957
TIMP-1 0.575 0.349–0.780 0.658 0.553 0.329–0.762
HA 0.783 0.558–0.928 0.866 0.929 0.736–0.994
PIIINP 0.792 0.567–0.933 0.875 0.894 0.689–0.984
doi:10.1371/journal.pone.0023218.t004
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laminin to one rich in fibril-forming collagen, like collagen type III
[44].
Concerning our results, there are different points to be
emphasized. First, the circulating concentration of TGF-ß1, HA,
TIMP-1, PIIINP were higher in CHC patients than in healthy
control subjects. Second, many markers seemed to be related to
liver fibrosis progression, but with different association patterns in
the two cohorts: TIMP-1 levels were associated with fibrosis
progression in the pediatric cohort and HA, PIIINP and TGF-ß1
in adults.
Many authors have explored these markers as a potential
noninvasive tool to predict fibrosis changes. Most of them
evaluated HA in adult HCV patients, and many applied a
combined panel of TIMP-1, PIIINP and HA named ELF test
[16,17,21,23,50]. This test which has shown good performance in
predicting advanced fibrosis, it is not commercially available
worldwide [10]. In our analysis, these above mentioned markers
seemed to be also related to liver fibrosis progression, but probably
not to be applied altogether as a panel. In accordance with the
results published by Patel et al [21], Sanvisens et al [18] and
Resino et al [50] our adult studied cohort displayed levels of HA
strongly associated with advanced stages of liver fibrosis.
Furthermore, our findings also go along with Saitou et al [16]
and Leroy et al [17] who described that both HA and PIIINP were
related to worse fibrosis stages. However, concerning TIMP-1
conflicting results were reported. Leroy et al [17] found association
between TIMP-1 levels and fibrosis stage in adults, while Macias et
al [24] did not. Interestingly our results were also discordant, since
no association was evidenced in adults but it was presented in
children. Although there are few data related to TIMP-1 in
children as a single marker of liver injury in different hepatic
diseases, our results suggested that TIMP-1 would be suitable as a
fibrosis marker in HCV children. This observation is in agreement
with data reported by Lebensztejn et al on pediatric HBV patients
[51], It is worthwhile to note that the highest TIMP-1 values were
those of the cirrhosis case, so it would be interesting to analyze
more cases from this condition to assess the actual diagnostic
accuracy for cirrhosis.
Diagnostic accuracy is evaluated using the area under the ROC
curve [30,31,32]. In the studied cohort most markers displayed an
AUROC increment between significant and advanced fibrosis.
According to Leroy et al [17] in our adult cohort HA and PIIINP
were also the markers with the best diagnostic accuracy for
advanced fibrosis. Moreover, HA showed moderate accuracy for
diagnosis of significant fibrosis (AUROC: 0.783), while it seemed
to be a very useful method for detection of advanced fibrosis
(AUROC: 0.929). This observation is in agreement with the data
published by many reports including adult monoinfected as well as
HIV/HCV coinfected patients [16,17,18,50]. Many authors have
described the reliability of this marker in series of pediatric HBV
infected patient as well as non-alcoholic fatty liver disease
[51,52,53,54,55,56]. Although in our HCV pediatric cohort HA
showed 100% specificity in advanced fibrosis, a remarkable point
for a diagnostic tool, it is usefulness seemed to be limited. Finally, a
novel finding was the TIMP-1 diagnostic accuracy for advanced
fibrosis which was described for the first time in HCV pediatric
series.
Poynard et al had proposed that for a disease defined as a
combination of stages vs. a combination of other stages, the
AUROCs for the diagnosis of it must be expressed in a
standardized fashion according to the prevalence of a given stage
[57]. They suggested to use a uniform distribution with the same
prevalence for each stage (corresponding to a difference in DANA
of 2.5 fibrosis METAVIR units between F$2 and F,2). This
finding is clinically significant, because it is easier to discuss the
apparently discordant results of a given biomarker observed in the
literature [29].Through the literature different AUROCs for
significant fibrosis concerning several markers were described.
Resino et al [50] reported an AUROC for HA of 0.676, while
Levoy et al [17] showed a HA AUROC of 0.75 and a PIIINP
AUROC of 0.77 and finally, Saitou et al [16] described an
AUROC of 0.805 for HA and of 0.747 for PIIINP. Based on their
population distribution published data we could assess DANA
values and estimate the AdAUROC for HA and PIIINP. When
comparing the HA and PIIINP AdAUROC results of our adult
series with the above mentioned estimated AdAUROCs; no
significant differences were observed. This confirms that although
our series is small, the conclusions drawn concerning the usefulness
of HA and PIIINP as fibrosis markers, are in accordance to the
data published in larger studies.
The facts that both HA and TGF-ß1 have close relationship
with stellate cells and that the activation of stellate cells is crucial
for developing hepatic fibrosis led to the hypothesis that serum
Table 5. Diagnostic accuracy of the serum markers measurement for significant and advance fibrosis.
Significant fibrosis (F$2) Advanced fibrosis (F$3)
Cut off Se% Sp% PPV NPV Cut off Se Sp PPV NPV
PEDIATRICS
TGF-ß1 (pg/ml) 6,950.6 87.5 44.4 73.7 66.7 8,755.7 60 70 33.3 87.5
TIMP-1 (ng/ml) 105.4 81.2 55.6 76.5 62.5 165.7 80 70 40 93.3
HA (ng/ml) 23.9 40 88.9 85.7 47.1 43.4 25 100 100 87
PIIINP (mg/L) 10.1 46.7 100 100 46.7 9.62 75 83.3 50 93.7
ADULTS
TGF-ß1 (pg/ml) 10,848.3 75 80 81.8 72.7 10,848.3 100 64.7 45.5 100
TIMP-1 (ng/ml) 336.2 41.7 80 71.4 53.3 654.8 20 100 100 81
HA (ng/ml) 103.1 66.7 90 89 62.2 109.7 100 82.3 62.5 100
PIIINP (mg/L) 9.1 75 80 81.8 72.7 9.1 100 64.7 45.5 100
Se: sensitivity Sp: specificity PPV: positive predictive value. NPV: negative predictive value.
In bold are shown the parameters for those markers with best AUROC.
doi:10.1371/journal.pone.0023218.t005
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with fibrosis [18]. However, the relationship between TGF-ß1, a
pro-fibrogenic cytokine, and the hepatic fibrosis is not well
established. Nelson et al [58] stated that fibrogenesis is a long
process and that the level of fibrosis was the summation of all the
effects in the past; therefore, active TGF-ß1 at a certain time point
might not correlate with the fibrosis score. In this study adult
TGF-ß1 levels displayed an inverse relationship with fibrosis
stages, where the lower TGF-ß1 values correspond to the worse
stages. Moreover, lower levels of TGF-ß1 were detected when
serum samples from 4 adult cirrhotic patients were included (data
no shown). In accordance with other authors, lower levels of TGF-
ß1 might indicate advanced liver fibrosis suggesting that this
marker may reflect fibrogenesis rather than fibrosis [59,60].
The final aim of a serum marker is to find molecules that mirror
liver fibrosis progression as an alternative of the biopsy when it is
contraindicated. In our cohort, all adult patients with advanced
fibrosis were correctly classified according to each cut off by HA,
PIIINP and TGF-ß1 markers. A better sorting of the cases should
be achieved if these markers were applied sequentially taking into
account their NPV and PPV. Given the diagnostic accuracy of HA
it would be chosen as the first line assay, then HA values over cut
off could be re-evaluated according either PIIINP or TGF-ß1 cut
off. Finally, only those cases with values over each marker cut off
should not avoid liver biopsy since it is the gold standard method
to assess actual damage of liver.
Finally, there are several reports that analyze APRI and AAR as
surrogate indirect serum markers of liver fibrosis. When assessed in
our cohorts, these approaches did not improve the diagnostic
accuracy performance of the proposed selected markers for each
group. In adults APRI showed a low performance which not reach
the 0.800 AUROC value proposed to be enough for staging
fibrosis, while AAR displayed a limited diagnostic value since it
only slightly improved the AUROC of TGF-ß1 to predict only
advanced fibrosis. (Table S1 and Figure S1). However, in the
pediatric series neither APRI nor AAR reached the 0.800
AUROC value, thus TIMP-1 remained to be the best option.
The present study does have several limitations. First, this was in
fact a retrospective study, with a quite limited number of cases, so
the small sample size makes it difficult to validate the utility of
serum markers. However, the results obtained from our adult
patients were similar to the ones reported in other larger adult
cohorts. Second, due to medical management protocols from our
institutions, pediatric patients without liver fibrosis (F0) and adults
with cirrhosis or hepatic decompensation were not available for
this study. Third, since we did not take into account biopsy length
and fragmentation, the potential for sampling error and under-
staging of fibrosis remains possible.
This study represents the first analysis performed on pediatric
chronic HCV patients and the first comparative study between
pediatric and adult cohorts related to a pro-fibrogenic cytokine
and matrix deposition markers. Our proposal represents a
significant step forward because we suggested that these markers
of fibrosis could be easily measured by a single assay without need
of special equipment and could be simply interpreted. The solely
evaluation of TIMP-1 may be enough to predict fibrosis in
children. The availability of a single marker test as TIMP-1, avoids
the need of not yet accessible complex tests, such as ELF, that
require the evaluation of predictive algorithms. Then, pediatric
patient with lower levels of TIMP-1 should avoid liver biopsy.
Continued monitoring of markers of liver fibrosis in pediatric
patients will help to establish their role in predicting clinical
outcomes. Serum TIMP-1 levels below the cut off values could act
as a surrogate marker of non-advanced liver fibrosis, thus
facilitating the clinical management of patients with HCV disease
when liver biopsy is unavailable or contraindicated. It would be
useful to study larger pediatric cohorts, perhaps in a multicentre
study, to validate and confirm our findings. Perhaps if these
parameters are validated in the near future, they would be so easy
to assess and interpret as are AST and ALT nowadays. In
consequence, this approach would be potentially translatable to
the bedside.
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